Kevin received his Ph.D. from the Department of Biology at MIT, where he made significant contributions to understanding the mechanisms that can contribute to cellular reprogramming. Following his doctoral studies, he launched his own group in the Department of Molecular and Cellular Biology at Harvard University, and became a principal tenured faculty member of the Harvard Stem Cell Institute.
A MacArthur Fellowship winner, Kevin’s laboratory at Harvard was the first to produce an iPSC-derived diseased cell type to model disease in a patient-specific manner. His research pursues strategies for using iPS cells in the development of new therapeutics. He has published some 130 scientific articles and has 13 patents. Scientific American named him as one of the Fifty Most Influential People in Science two years in a row.
Kevin is currently with the innovative biotech company BioMarin. As Group Vice President, Head of Research and Early Development he is responsible for the execution of BioMarin’s discovery research programs, playing a critical role in shaping the vision of the company’s future research pipeline. He heads BioMarin’s Research organization, providing scientific leadership throughout the drug discovery process.